Abstract
Low bone mineral density (BMD) prevails among patients with schizophrenia. Antipsychotics use plays an important role in BMD. Previous cross-section study suggests that clozapine treatment may benefit BMD of women with schizophrenia. However, the effect of long-term clozapine therapy on BMD remains unknown. This prospective study compared clozapine and non-clozapine antipsychotics in long-term effects on BMD among both men and women with schizophrenia. Patients with schizophrenia and age-matched healthy individuals were enrolled from two centers. All patients, including clozapine receivers and non-clozapine antipsychotics recipients, kept clinically stable with unchanged antipsychotics and doses for at least 6 months at enrollment and during the follow-up period. BMD was examined by dual-energy X-ray absorptiometer upon enrollment and at 1- or 3-year follow-up. Thorough clinical and laboratory variables were measured too. The mean BMD of patients receiving clozapine was higher than that of the non-clozapine patients at both enrollment and follow-up. Overall, the patients in the clozapine group gained BMD, while those in the non-clozapine group lost BMD after 1–3 years (p = 0.015). There was no significant difference of BMD change between clozapine-treated patients and healthy controls. Factors associated with BMD change in the clozapine group included calcium level (B = −0.607, p = 0.021) and T3 level (B = −0.077, p = 0.007). This longitudinal study suggests that long-term clozapine treatment may protect BMD compared to prolactin-raising and non-clozapine prolactin-sparing antipsychotics among patients with schizophrenia. Future prospective studies are warranted to testify whether switching from non-clozapine antipsychotics to clozapine can rescue BMD.
Highlights
The long-term impacts of various antipsychotics on bone mineral density (BMD) have been gaining more attention[6,7]
Our previous study found that women with schizophrenia receiving clozapine had better BMD than those taking PR antipsychotic treatment; there was no correlation between prolactin level and BMD12
Patients with schizophrenia were classified into two groups to the antipsychotics they had been taking: clozapine group and non-clozapine antipsychotics group
Summary
The long-term impacts of various antipsychotics on BMD have been gaining more attention[6,7]. Our previous study found that women with schizophrenia receiving clozapine had better BMD than those taking PR antipsychotic treatment; there was no correlation between prolactin level and BMD12. NMDARs are expressed in osteoblasts and osteoclasts[22,23], and down-regulation of NMDARs may result in the decrease of osteogenesis[24] It has not yet been clear whether clozapine exerts different effects on BMD compared to other antipsychotics, non-clozapine PS antipsychotics that do not cause hyperprolactinemia. This study prospectively followed up BMD for one to three years in both male and female patients with schizophrenia under stable antipsychotics treatment and in healthy men and women, aiming to investigate the long-term effect of clozapine vs non-clozapine antipsychotics (including PR and non-clozapine PS antipsychotics) on BMD
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
